{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:50:25Z","timestamp":1791510625722,"version":"4.3.4"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutical Science Advances"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.pscia.2024.100052","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T23:11:13Z","timestamp":1725750673000},"page":"100052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Novel targeted therapies in chronic myeloid leukemia"],"prefix":"10.1016","volume":"2","author":[{"given":"Muhammad Sameer","family":"Ashaq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8522-4764","authenticated-orcid":false,"given":"Baobing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pscia.2024.100052_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s12185-022-03510-w","article-title":"Genetic landscape of chronic myeloid leukemia","volume":"117","author":"Ochi","year":"2023","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.pscia.2024.100052_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030620","article-title":"Genomic mechanisms influencing outcome in chronic myeloid leukemia","volume":"14","author":"Fernandes","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.pscia.2024.100052_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1308709","article-title":"The dark side of stemness\u2013the role of hematopoietic stem cells in development of blood malignancies,","volume":"14","author":"Filipek-Gorza\u0142a","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.pscia.2024.100052_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic myeloid leukemia: modern therapies, current challenges and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev."},{"key":"10.1016\/j.pscia.2024.100052_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/02841868309134332","article-title":"Splenic irradiation in chronic myeloid leukemia","volume":"22","author":"Hukku","year":"1983","journal-title":"Acta Radiologica Oncol"},{"key":"10.1016\/j.pscia.2024.100052_bib6","first-page":"691","volume":"95","author":"Jabbour","year":"2020","journal-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring"},{"key":"10.1016\/j.pscia.2024.100052_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11899-022-00679-z","article-title":"Therapy resistance and disease progression in CML: mechanistic links and therapeutic strategies","volume":"17","author":"Ng","year":"2022","journal-title":"Curr. Hematol. Malig. Rep"},{"key":"10.1016\/j.pscia.2024.100052_bib8","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.gendis.2023.01.008","article-title":"Signaling pathways governing the behaviors of leukemia stem cells","volume":"11","author":"Azizidoost","year":"2024","journal-title":"Gene. Dis"},{"key":"10.1016\/j.pscia.2024.100052_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143300","article-title":"Mechanisms of resistance and implications for treatment strategies in chronic myeloid leukaemia","volume":"14","author":"Poudel","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.pscia.2024.100052_bib10","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-021-02659-1","article-title":"Chronic myeloid leukemia stem cells: targeting therapeutic implications","volume":"12","author":"Mojtahedi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.pscia.2024.100052_bib11","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","article-title":"Chronic myeloid leukemia stem cells","volume":"33","author":"Houshmand","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.pscia.2024.100052_bib12","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.pscia.2024.100052_bib13","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pscia.2024.100052_bib14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11899-023-00703-w","article-title":"Real-world Management of CML: outcomes and treatment patterns","volume":"18","author":"Held","year":"2023","journal-title":"Curr. Hematol. Malig. Rep"},{"key":"10.1016\/j.pscia.2024.100052_bib15","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.2174\/0929867328666211012093423","article-title":"Research status, synthesis and clinical application of recently marketed and clinical BCR-ABL inhibitors","volume":"29","author":"Xu","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.pscia.2024.100052_bib16","article-title":"Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia","volume":"13","author":"Jiang","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.pscia.2024.100052_bib17","first-page":"454","article-title":"Frontline flumatinib versus imatinib in patients with chronic myeloid leukemia in chronic phase: results from the China randomized phase III study, Am. Soc. Clin","volume":"10","author":"Li","year":"2019","journal-title":"Oncol."},{"key":"10.1016\/j.pscia.2024.100052_bib18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2020-142142","article-title":"Novel BCR-ABL1 tyrosine kinase inhibitor (TKI) HQP1351 (olverembatinib) is efficacious and well tolerated in patients with T315I-mutated chronic myeloid leukemia (CML): results of pivotal (phase II) trials","volume":"136","author":"Jiang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pscia.2024.100052_bib19","article-title":"Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial","volume":"15","author":"Jiang","year":"2022","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.pscia.2024.100052_bib20","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-129751","article-title":"Phase 1 trial of K0706, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI): in patients with chronic myelogenous leukemia (CML) and Phildelphia positive acute lymphoblastic leukemia (Ph+ ALL) failing \u2265 3 prior TKI therapies: initial safety and efficacy","volume":"134","author":"Cortes","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pscia.2024.100052_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2020-139847","article-title":"Phase 1 trial of vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI): activity in CML chronic phase patients failing TKI therapies including ponatinib","volume":"136","author":"Cortes","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.pscia.2024.100052_bib22","first-page":"289","article-title":"PF-114, a novel selective inhibitor of BCR-ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells","volume":"55","author":"Ivanova","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.pscia.2024.100052_bib23","first-page":"1","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.pscia.2024.100052_bib24","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127951","article-title":"PF-114: a 4th generation tyrosine kinase-inhibitor for chronic phase chronic myeloid leukaemia including BCRABL1T315I","volume":"134","author":"Turkina","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pscia.2024.100052_bib25","article-title":"Harmonizing the craft of crafting clinically endorsed small-molecule BCR-ABL tyrosine kinase inhibitors for the treatment of hematological malignancies, Eur","volume":"106678","author":"Sun","year":"2023","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.pscia.2024.100052_bib26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3324\/haematol.2016.152710","article-title":"Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia","volume":"102","author":"Cortes","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.pscia.2024.100052_bib27","article-title":"e19164","volume":"6","author":"Balabanov","year":"2011","journal-title":"Abcg2 overexpression represents a novel mechanism for acquired resistance"},{"key":"10.1016\/j.pscia.2024.100052_bib28","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/annonc\/mdr451","article-title":"A\u00a0phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies,","volume":"23","author":"Arkenau","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.pscia.2024.100052_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43556-021-00030-7","article-title":"Cancer non-stem cells as a potent regulator of tumor microenvironment: a lesson from chronic myeloid leukemia","volume":"2","author":"Mukaida","year":"2021","journal-title":"Mol. Biomed"},{"key":"10.1016\/j.pscia.2024.100052_bib30","first-page":"1","article-title":"Reactive oxygen species in BCR-ABL1-expressing cells\u2013relevance to chronic myeloid leukemia","volume":"64","author":"Antoszewska-Smith","year":"2017","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.pscia.2024.100052_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030958","article-title":"The Hedgehog pathway as a therapeutic target in chronic myeloid leukemia","volume":"15","author":"Wu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pscia.2024.100052_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.176","article-title":"Signaling pathways in the regulation of cancer stem cells and associated targeted therapy","volume":"3","author":"Manni","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.pscia.2024.100052_bib33","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1172\/JCI127080","article-title":"SIRT1 regulates metabolism and leukemogenic potential in CML stem cells","volume":"129","author":"Abraham","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.pscia.2024.100052_bib34","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.pscia.2024.100052_bib35","article-title":"PI3K\/Akt\/mTOR signaling pathway in cancer stem cells, Pathol. Res. Pract","volume":"154010","author":"Ebrahimi","year":"2022","journal-title":"237"},{"key":"10.1016\/j.pscia.2024.100052_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2018.00446","article-title":"Metformin, an anti-diabetic drug to target leukemia","volume":"9","author":"Biondani","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.pscia.2024.100052_bib37","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/CAD.0000000000000266","article-title":"The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell,","volume":"26","author":"Shi","year":"2015","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.pscia.2024.100052_bib38","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1111\/jcmm.17228","article-title":"JAK-STAT core cancer pathway: an integrative cancer interactome analysis","volume":"26","author":"Erdogan","year":"2022","journal-title":"J.\u00a0Cell Mol. Med."},{"key":"10.1016\/j.pscia.2024.100052_bib39","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1172\/JCI79196","article-title":"Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells","volume":"126","author":"Zhang","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.pscia.2024.100052_bib40","first-page":"115","article-title":"Novel approaches to therapy in CML, Hematology 2014, Am. Soc. Hematol","volume":"2017","author":"Bhatia","year":"2017","journal-title":"Education Program Book"},{"key":"10.1016\/j.pscia.2024.100052_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0805-1","article-title":"Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia","volume":"17","author":"Massimino","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.pscia.2024.100052_bib42","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of \u03b2-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pscia.2024.100052_bib43","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/leu.2017.87","article-title":"Combined inhibition of \u03b2-catenin and Bcr\u2013Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo","volume":"31","author":"Zhou","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.pscia.2024.100052_bib44","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.stem.2020.04.005","article-title":"Integrin-linked kinase mediates therapeutic resistance of quiescent CML stem cells to tyrosine kinase inhibitors","volume":"27","author":"Rothe","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.pscia.2024.100052_bib45","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.54.54","article-title":"Inhibition of CML stem cell renewal by the porcupine inhibitor WNT974","volume":"126","author":"Agarwal","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.pscia.2024.100052_bib46","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2016-05-714089","article-title":"Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI","volume":"129","author":"Agarwal","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pscia.2024.100052_bib47","doi-asserted-by":"crossref","first-page":"e399","DOI":"10.3324\/haematol.2019.229997","article-title":"CD34+ acute myeloid leukemia cells with low levels of reactive oxygen species show increased expression of stemness genes and can be targeted by the BCL2 inhibitor venetoclax","volume":"105","author":"Mattes","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.pscia.2024.100052_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1180","article-title":"Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells","volume":"8","author":"Carter","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pscia.2024.100052_bib49","first-page":"1","article-title":"Future directions in chronic phase CML treatment, Curr","author":"Javidi-Sharifi","year":"2021","journal-title":"Hematol. Malig. Rep"},{"key":"10.1016\/j.pscia.2024.100052_bib50","doi-asserted-by":"crossref","first-page":"E2298","DOI":"10.1073\/pnas.1301838110","article-title":"Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function","volume":"110","author":"Lim","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.pscia.2024.100052_bib51","doi-asserted-by":"crossref","first-page":"43662","DOI":"10.18632\/oncotarget.18216","article-title":"Targeting BCR-ABL+ stem\/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pscia.2024.100052_bib52","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/1878-0261.12186","article-title":"Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-\u03baB pathways in a model of chronic myeloid leukemia","volume":"12","author":"Chorzalska","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.pscia.2024.100052_bib53","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1182\/blood.2021011043","article-title":"Breakthrough science: hypoxia-inducible factors, oxygen sensing, and disorders of hematopoiesis","volume":"139","author":"Semenza","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.pscia.2024.100052_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00665","article-title":"New approaches and treatment combinations for the management of chronic myeloid leukemia","volume":"9","author":"Westerweel","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.pscia.2024.100052_bib55","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pscia.2024.100052_bib56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/cbdd.12737","article-title":"Peroxisome proliferator-activated receptor ligands and their role in chronic myeloid leukemia: therapeutic strategies","volume":"88","author":"Yousefi","year":"2016","journal-title":"Chem. Biol. Drug Design"},{"key":"10.1016\/j.pscia.2024.100052_bib57","first-page":"1","article-title":"d.C.C. Melo, K.P.V. Ferro, A.d.S.S. Duarte, S.T. Olalla Saad, CXCR7 participates in CXCL12-mediated migration and homing of leukemic and normal hematopoietic cells","volume":"9","author":"R","year":"2018","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.pscia.2024.100052_bib58","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.22409","article-title":"Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition","volume":"8","author":"Weisberg","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pscia.2024.100052_bib59","series-title":"In the Pipeline: Emerging Therapy for CML, Pathogenesis and Treatment of Leukemia, Springer","first-page":"663","author":"Gill","year":"2023"},{"key":"10.1016\/j.pscia.2024.100052_bib60","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.stem.2017.08.001","article-title":"Prostaglandin E1 and its analog misoprostol inhibit human CML stem cell self-renewal via EP4 receptor activation and repression of AP-1","volume":"21","author":"Li","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.pscia.2024.100052_bib61","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3324\/haematol.2019.234898","article-title":"Defining niche interactions to target chronic myeloid leukemia stem cells","volume":"105","author":"Mitchell","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.pscia.2024.100052_bib62","first-page":"1175","article-title":"Requirement for CD44 in homing and engraftment of BCR-ABL\u2013expressing leukemic stem cells, Nat","volume":"12","author":"Krause","year":"2006","journal-title":"Med"},{"key":"10.1016\/j.pscia.2024.100052_bib63","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3324\/haematol.2018.212365","article-title":"The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin-SCL\/TAL1-CD44 axis,","volume":"105","author":"Godavarthy","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.pscia.2024.100052_bib64","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.gendis.2023.02.039","article-title":"HIF-1\u03b1 signaling: essential roles in tumorigenesis and implications in targeted therapies","volume":"11","author":"Zhao","year":"2024","journal-title":"Gene Dis"},{"key":"10.1016\/j.pscia.2024.100052_bib65","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2016-10-745588","article-title":"Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine","volume":"130","author":"Cheloni","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pscia.2024.100052_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030544","article-title":"The role of MYC and PP2A in the initiation and progression of myeloid leukemias","volume":"9","author":"Pippa","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.pscia.2024.100052_bib67","article-title":"Inhibition of c-Myc using 10058-F4 induces anti-tumor effects in ovarian cancer cells via regulation of FOXO target genes, Eur","volume":"908","author":"Ghaffarnia","year":"2021","journal-title":"J.\u00a0Pharmacol."},{"key":"10.1016\/j.pscia.2024.100052_bib68","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1158\/1078-0432.CCR-13-2575","article-title":"Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia","volume":"20","author":"Agarwal","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.pscia.2024.100052_bib69","first-page":"45","article-title":"Strategies for targeting chronic myeloid leukaemia stem cells, Blood Lymphat","author":"Carra","year":"2019","journal-title":"Cancer: Targets Ther"},{"key":"10.1016\/j.pscia.2024.100052_bib70","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.pscia.2024.100052_bib71","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3324\/haematol.2019.246306","article-title":"Recruiting TP53 to target chronic myeloid leukemia stem cells","volume":"105","author":"Grant","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.pscia.2024.100052_bib72","article-title":"Targeting p53\u2013MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials","volume":"15","author":"Zhu","year":"2022","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.pscia.2024.100052_bib73","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1080\/10428194.2016.1272682","article-title":"Induction of p53 suppresses chronic myeloid leukemia","volume":"58","author":"Peterson","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.pscia.2024.100052_bib74","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/CAD.0000000000000651","article-title":"RITA induces apoptosis in p53-null K562 leukemia cells by inhibiting STAT5, Akt, and NF-\u03baB signaling pathways","volume":"29","author":"Mobaraki","year":"2018","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.pscia.2024.100052_bib75","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1182\/blood-2016-07-728873","article-title":"Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML","volume":"129","author":"Warfvinge","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pscia.2024.100052_bib76","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1158\/0008-5472.CAN-18-1078","article-title":"CML hematopoietic stem cells expressing IL1RAP can be targeted by chimeric antigen receptor\u2013engineered T cells","volume":"79","author":"Warda","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.pscia.2024.100052_bib77","doi-asserted-by":"crossref","first-page":"16280","DOI":"10.1073\/pnas.1004408107","article-title":"Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein","volume":"107","author":"J\u00e4r\u00e5s","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.pscia.2024.100052_bib78","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3324\/haematol.2017.169946","article-title":"CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting","volume":"103","author":"Landberg","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.pscia.2024.100052_bib79","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","article-title":"Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche","volume":"19","author":"Ye","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.pscia.2024.100052_bib80","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2013-07-517847","article-title":"The IL-2\/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells,","volume":"123","author":"Kobayashi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pscia.2024.100052_bib81","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1158\/1078-0432.CCR-15-0767","article-title":"Identification of CD25 as STAT5-dependent growth regulator of leukemic stem cells in Ph+ CML","volume":"22","author":"Sadovnik","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.pscia.2024.100052_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-020-00839-z","article-title":"Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL\/MYC-signaling: effect on imatinib resistance and stem cells","volume":"12","author":"Lernoux","year":"2020","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.pscia.2024.100052_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-020-00839-z","article-title":"Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL\/MYC-signaling: effect on imatinib resistance and stem cells","volume":"12","author":"Lernoux","year":"2020","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.pscia.2024.100052_bib84","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.yexcr.2018.07.017","article-title":"HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR\/ABL1","volume":"370","author":"Bamodu","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.pscia.2024.100052_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110390","article-title":"A\u00a0novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells,","volume":"129","author":"He","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.pscia.2024.100052_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071639","article-title":"EZH2 in myeloid malignancies","volume":"9","author":"Rinke","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.pscia.2024.100052_bib87","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-15-1439","article-title":"Chronic myelogenous leukemia\u2013initiating cells require Polycomb group protein EZH2","volume":"6","author":"Xie","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.pscia.2024.100052_bib88","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-111126","article-title":"BRD4 degradation is a potent approach to block MYC expression and to overcome multiple forms of stem cell resistance in Ph+ CML","volume":"132","author":"Peter","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pscia.2024.100052_bib89","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/leu.2016.355","article-title":"Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma","volume":"31","author":"Siu","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.pscia.2024.100052_bib90","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.scib.2021.01.004","article-title":"A\u00a0systematic survey of PRMT interactomes reveals the key roles of arginine methylation in the global control of RNA splicing and translation","volume":"66","author":"Wei","year":"2021","journal-title":"Sci. Bull."},{"key":"10.1016\/j.pscia.2024.100052_bib91","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1172\/JCI85239","article-title":"Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia","volume":"126","author":"Jin","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.pscia.2024.100052_bib92","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cmet.2022.04.004","article-title":"Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML","volume":"34","author":"Liu","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.pscia.2024.100052_bib93","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2016-10-745588","article-title":"Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine","volume":"130","author":"Cheloni","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pscia.2024.100052_bib94","article-title":"Inhibition of c-Myc using 10058-F4 induces anti-tumor effects in ovarian cancer cells via regulation of FOXO target genes, Eur","volume":"908","author":"Ghaffarnia","year":"2021","journal-title":"J.\u00a0Pharmacol."},{"key":"10.1016\/j.pscia.2024.100052_bib95","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1158\/1078-0432.CCR-13-2575","article-title":"Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia","volume":"20","author":"Agarwal","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.pscia.2024.100052_bib96","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.exphem.2017.09.012","article-title":"Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia","volume":"57","author":"Willmann","year":"2018","journal-title":"Exp. Hematol"},{"key":"10.1016\/j.pscia.2024.100052_bib97","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/s12185-021-03112-y","article-title":"New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism","volume":"113","author":"Naka","year":"2021","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.pscia.2024.100052_bib98","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.3324\/haematol.2019.219261","article-title":"Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem\/progenitor cells in a murine model","volume":"105","author":"Carter","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.pscia.2024.100052_bib99","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-115709","article-title":"SIRT1 mediates enhanced mitochondrial oxidative phosphorylation in chronic myelogenous leukemia stem cells","volume":"132","author":"Abraham","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pscia.2024.100052_bib100","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/978-981-15-4272-5_43","article-title":"Autophagy and leukemia","author":"Zheng","year":"2020","journal-title":"Autophagy: Biol. Dis.: Clin. Sci"},{"key":"10.1016\/j.pscia.2024.100052_bib101","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1172\/JCI81135","article-title":"The biology and function of exosomes in cancer,","volume":"126","author":"Kalluri","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.pscia.2024.100052_bib102","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2174\/15680096113139990088","article-title":"Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy","volume":"13","author":"V Helgason","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.pscia.2024.100052_bib103","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/ijc.26217","article-title":"Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis","volume":"130","author":"Taverna","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.pscia.2024.100052_bib104","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/bph.12183","article-title":"Targeting survival pathways in chronic myeloid leukaemia stem cells","volume":"169","author":"Sinclair","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pscia.2024.100052_bib105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14728214.2018.1445717","article-title":"Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia","volume":"23","author":"Kavanagh","year":"2018","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.pscia.2024.100052_bib106","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/cgt.2016.80","article-title":"Therapeutic vaccination based on side population cells transduced by the granulocyte\u2013macrophage colony-stimulating factor gene elicits potent antitumor immunity","volume":"24","author":"Sakamoto","year":"2017","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.pscia.2024.100052_bib107","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/leu.2015.26","article-title":"Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells","volume":"29","author":"Riether","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.pscia.2024.100052_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120437","article-title":"The role of microRNAs in the development, progression and drug resistance of chronic myeloid leukemia and their potential clinical significance","volume":"296","author":"Navabi","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.pscia.2024.100052_bib109","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s11010-022-04576-0","article-title":"Jyotirmayee, M. Verma, Developing therapeutic approaches for chronic myeloid leukemia: a review","volume":"478","author":"Kumar","year":"2023","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.pscia.2024.100052_bib110","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1016\/j.pscia.2026.100151","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000}}],"container-title":["Pharmaceutical Science Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2773216924000187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2773216924000187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T11:55:47Z","timestamp":1733486147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2773216924000187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":110,"alternative-id":["S2773216924000187"],"URL":"https:\/\/doi.org\/10.1016\/j.pscia.2024.100052","relation":{},"ISSN":["2773-2169"],"issn-type":[{"value":"2773-2169","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel targeted therapies in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Pharmaceutical Science Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pscia.2024.100052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of Shandong University.","name":"copyright","label":"Copyright"}],"article-number":"100052"}}